Enliven Therapeutics (ELVN) PT Raised to $45 at Mizuho, 'Still an under-rated asset in the CML space'

March 24, 2026 3:04 PM

Mizuho analyst Salim Syed raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $45.00 (from $41.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found